Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs ALOGLIPTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus,Combination therapy with metformin, sulfonylurea, thiazolidinedione, or insulin
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
25 mg orally once daily
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Alogliptin is minimally metabolized; approximately 60-70% excreted unchanged in urine. Metabolism involves hepatic microsomal enzymes, primarily CYP2D6 and CYP3A4, but to a minor extent.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
20% bound to plasma proteins, primarily albumin. Binding is concentration-independent.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Volume of distribution is approximately 33 L (0.47 L/kg assuming 70 kg). This suggests distribution into total body water, but not extensive tissue binding.
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
Oral bioavailability is approximately 100%, indicating complete absorption with minimal first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
e GFR 30-59 m L/min: 12.5 mg orally once daily; e GFR 15-29 m L/min: 6.25 mg orally once daily; e GFR <15 m L/min or dialysis: 6.25 mg orally once daily
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B); not recommended for severe hepatic impairment (Child-Pugh C)
Not indicated for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established; no recommended dosing available
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
No dose adjustment recommended based on age alone; monitor renal function and adjust dose accordingly
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
None.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Pancreatitis: Cases of acute pancreatitis have been reported; discontinue if pancreatitis is suspected.,Hypersensitivity reactions: Including anaphylaxis, angioedema, and severe cutaneous adverse reactions.,Heart failure: Consider risk factors; monitor for signs and symptoms.,Severe and disabling arthralgia has been reported.,Acute renal failure: Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) or end-stage renal disease.,Hypoglycemia when used in combination with insulin or sulfonylureas.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
History of serious hypersensitivity reaction to alogliptin or any excipient,Type 1 diabetes mellitus,Diabetic ketoacidosis
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
No specific food interactions; can be taken with or without food. Avoid excessive alcohol intake due to potential hypoglycemia risk when used with other agents.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and well-controlled studies in pregnant women exist. Use only if clearly needed. First trimester risk cannot be ruled out; limited human data.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
It is unknown if alogliptin is excreted in human breast milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account importance to the mother.
Not applicable; contraindicated in pregnancy.
No specific dose adjustments recommended; however, pregnancy may alter pharmacokinetics of alogliptin. Avoid use when possible, particularly during the second and third trimesters, due to limited safety data.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Alogliptin is a DPP-4 inhibitor with minimal risk of hypoglycemia when used as monotherapy; dosing adjustments required for renal impairment (creatinine clearance <60 m L/min). Monitor for acute pancreatitis and severe arthralgia. No significant weight loss or gain. Use with caution in patients with history of pancreatitis.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
Take alogliptin with or without food once daily.,Do not skip meals, especially if taking other diabetes medications that cause hypoglycemia.,Contact healthcare provider immediately if you experience persistent severe abdominal pain (sign of pancreatitis).,Report any joint pain that is new or worsening.,Store at room temperature away from moisture and heat.
No interactions on record
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Sunitinib, a tyrosine kinase inhibitor, may enhance the glucose-lowering effects of alogliptin, a DPP-4 inhibitor, by impairing renal function and potentially reducing the renal clearance of alogliptin, leading to increased exposure and risk of hypoglycemia. This interaction is particularly relevant in patients with pre-existing renal impairment or those receiving high-dose sunitinib. Clinical outcomes include episodes of symptomatic hypoglycemia, which may require dose adjustment of antidiabetic therapy."
"Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, enhancing glucose-dependent insulin secretion. Mesalazine, known for its anti-inflammatory effects in inflammatory bowel disease, may independently lower blood glucose via unknown mechanisms. Concurrent use could potentiate hypoglycemic effects, especially in patients with diabetes or impaired glucose regulation, increasing the risk of symptomatic hypoglycemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs ALOGLIPTIN, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. ALOGLIPTIN is a DPP-4 Inhibitor that works by Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and ALOGLIPTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of ALOGLIPTIN is: 25 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and ALOGLIPTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. ALOGLIPTIN is classified as Category C. Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and we. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.